Publications by authors named "Taub R"

Communication can be a challenge for a significant minority of the population. Those with intellectual disability, autism, or Stroke survivors can encounter significant problems and stigma in their communication abilities leading to worse health and social outcomes. SpeechMatch (https://www.

View Article and Find Full Text PDF
Article Synopsis
  • Resmetirom, a thyroid-hormone receptor-β agonist, has been approved for treating metabolic dysfunction-associated steatohepatitis (MASH), and its impact on health-related quality of life (HRQL) was studied in this clinical trial.
  • In a 54-month double-blind trial with nearly 1,000 patients, those receiving resmetirom (80 mg or 100 mg) showed significant improvements in various HRQL measures compared to a placebo group, particularly in the Worry domain of the Chronic Liver Disease Questionnaire (CLDQ-NAFLD).
  • The study concluded that patients with MASH/NASH who improved their fibrosis or resolved MASH experienced notable HRQL enhancements, indicating that resmeti
View Article and Find Full Text PDF

Machine learning, and representation learning in particular, has the potential to facilitate drug discovery by screening a large chemical space in silico. A successful approach for representing molecules is to treat them as graphs and utilize graph neural networks. One of the key limitations of such methods is the necessity to represent compounds with different numbers of atoms, which requires aggregating the atom's information.

View Article and Find Full Text PDF

Background: Fibromyalgia (FM) is a pain condition characterized by physical and psychological difficulties. This randomized controlled trial aimed to evaluate the effects of a mindfulness-based stress reduction (MBSR) on FM patients and identify the role of two pain cognitions: psychological inflexibility in pain (PIPS) and pain catastrophizing (PCS), as mechanisms of change.

Methods: 95 FM patients (Mean ± SD: 49.

View Article and Find Full Text PDF
Article Synopsis
  • * A phase 3 trial is underway, where adult participants with confirmed NASH are randomly assigned to receive either resmetirom (80 mg or 100 mg) or a placebo, with primary goals of NASH resolution and improvement in fibrosis after 52 weeks.
  • * In the trial's results, a significantly higher percentage of patients taking resmetirom experienced NASH resolution and fibrosis improvement compared to those on placebo, along with notable reductions in cholesterol levels, although some participants did report diarrhea.
View Article and Find Full Text PDF
Article Synopsis
  • Nonalcoholic steatohepatitis (NASH) is a serious liver disease that currently has no approved treatments; a recent trial called MAESTRO-NAFLD-1 tested a drug called resmetirom for safety and efficacy in adults with this condition.
  • In the 52-week trial involving over 1,000 participants, patients were given different doses of resmetirom or a placebo, and researchers focused on side effects and various health markers like liver fat and cholesterol levels.
  • The results showed that resmetirom was generally safe and well tolerated, with reported side effects like diarrhea and nausea, while also leading to significant reductions in liver fat and cholesterol levels compared to placebo, suggesting its potential for further development
View Article and Find Full Text PDF
Article Synopsis
  • Non-alcoholic steatohepatitis (NASH) is a severe liver disease that can progress from non-alcoholic fatty liver disease (NAFLD), characterized by fat accumulation and liver damage.
  • The MAESTRO clinical program includes multiple Phase 3 trials to evaluate the efficacy and safety of resmetirom, a targeted thyroid hormone receptor-β agonist, for treating NASH, with various study designs involving liver biopsies and patient-reported outcomes.
  • The goal of these trials is to gather robust evidence to support the approval of resmetirom in treating NASH by assessing both immediate biopsy results and long-term liver health outcomes.
View Article and Find Full Text PDF

Purpose: Bladder cancer represents 3% of all new cancer diagnoses per year. We propose intravesical radionuclide therapy using the β-emitter Y linked to DOTA-biotin-avidin ([Y]DBA) to deliver short-range radiation against non-muscle invasive bladder cancer (NMIBC).

Material And Methods: Image-guided biodistribution of intravesical DBA was investigated in an animal model by radiolabeling DBA with the Ga and dynamic microPET imaging following intravesical infusion of [Ga]DBA for up to 4 h and post-necropsy γ-counting of organs.

View Article and Find Full Text PDF

Background: The psychological effects of systemic lupus erythematosus (SLE) are tremendous. This pilot mixed-methods randomized controlled trial aimed to evaluate the effects of a mindfulness-based stress reduction (MBSR) adapted protocol on psychological distress among SLE patients.

Methods: 26 SLE patients were randomly assigned to MBSR group therapy ( = 15) or a waitlist (WL) group ( = 11).

View Article and Find Full Text PDF
Article Synopsis
  • A phase 2 clinical trial enrolled 125 patients with confirmed NASH, comparing results from those treated with resmetirom versus a placebo over 36 weeks, using the Short Form-36 to measure HRQL.
  • Results showed that patients receiving resmetirom had significant HRQL improvements, particularly in Bodily Pain and overall physical functioning, especially if they also saw a reduction in liver fat, indicating potential benefits of treating NASH.
View Article and Find Full Text PDF

It is nearly impossible to separate two interleaved phonebooks by pulling their spines. The very slight force exerted by the outer sheets of the assembly is amplified as the exponential of the square of the number of sheets, meaning that even a small number of sheets can create a highly resistant system. We present a systematic and detailed study of the influences of the normal external force and the geometrical parameters of the booklets on the assembly strength.

View Article and Find Full Text PDF
Article Synopsis
  • Resmetirom (MGL-3196) is a thyroid hormone receptor-β agonist that was tested over 36 weeks in adults with nonalcoholic steatohepatitis (NASH), primarily focusing on reducing liver fat using MRI-PDFF as the main measure.
  • In the open-label extension study, patients taking resmetirom showed significant reductions in liver fat (mean reduction -11.1% and relative reduction -52.3%), as well as lowered LDL cholesterol, apolipoprotein B, and triglycerides.
  • Overall, resmetirom was well tolerated with few side effects, indicating its safety and effectiveness for treating NASH and potential for monitoring liver response non-invasively.*
View Article and Find Full Text PDF

Background: An estimated 1.4 million persons in the United States identify as transgender or nonbinary, signifying that their gender identity does not correspond with their assigned sex at birth. Individuals assigned female at birth may seek gender-affirming hormone therapy with testosterone.

View Article and Find Full Text PDF

Signalling is of particular importance in immune cells, and upstream in the signalling pathway many membrane receptors are functional only as complexes, co-locating with particular lipid species. Work over the last 15 years has shown that plasma membrane lipid composition is close to a critical point of phase separation, with evidence that cells adapt their composition in ways that alter the proximity to this thermodynamic point. Macrophage cells are a key component of the innate immune system, are responsive to infections and regulate the local state of inflammation.

View Article and Find Full Text PDF

Purpose: Cytoreductive surgery with intraoperative hyperthermic intraperitoneal chemotherapy is standard of care for diffuse malignant peritoneal mesothelioma (DMPM), but there is variability among institutions in the administration of adjuvant chemotherapy. Characterization of the largest series of DMPM patients treated at a single institution and identification of the demographic, disease, and treatment factors associated with overall survival were sought.

Patients And Methods: All DMPM patients who underwent initial cytoreductive surgery with the intention to undergo intraperitoneal chemotherapy and a second-look operation from 1995 to 2016 at our institution were retrospectively reviewed.

View Article and Find Full Text PDF
Article Synopsis
  • Non-alcoholic steatohepatitis (NASH) is a liver condition characterized by fat accumulation, inflammation, and liver injury, and the study focused on resmetirom (MGL-3196), a thyroid hormone receptor-β agonist, aimed at improving NASH.
  • A randomized, double-blind study involved 84 participants with confirmed NASH, comparing resmetirom to a placebo over 36 weeks, assessing liver fat using MRI and liver biopsies.
  • Results showed that resmetirom significantly reduced liver fat at both 12 weeks (-32.9% vs -10.4% for placebo) and 36 weeks (-37.3% vs -8.5%), with mostly mild side
View Article and Find Full Text PDF

Background: The most common sites of malignant mesothelioma are the pleura and peritoneum, but little is known about the incidence, prognosis, or treatment of patients with disease in both cavities. Previous series suggest that multimodality treatment improves overall survival for pleural or peritoneal disease, but studies typically exclude patients with disease in both cavities. Despite limitations, this investigation is the only study to broadly examine outcomes for patients with malignant mesothelioma in both the pleural and peritoneal cavities.

View Article and Find Full Text PDF

Context: - Diagnosis of malignant mesothelioma is more common in the chest than it is in the abdomen. Most published immunohistochemistry data are more applicable to pleural than to peritoneal mesothelioma.

Objective: - To clarify the practical utility of 17 immunohistochemistry markers in the differential diagnosis of peritoneal mesothelioma with an emphasis on stains for which there is either contradictory information or a paucity of literature.

View Article and Find Full Text PDF

Background: The prognosis for patients with diffuse malignant peritoneal mesothelioma has dramatically improved with cytoreductive surgery and intraperitoneal chemotherapy. Little is known about disease recurrence after treatment. We analyzed the time to and predictors of recurrence in a large cohort of optimally treated patients.

View Article and Find Full Text PDF

Objectives: Cervical mucus varies in response to both natural and artificial hormonal changes. It is commonly believed that cervical mucus thinning is associated with normal fertility and that progestogen-induced thickening is an essential contraceptive mechanism. This review aims to broadly summarize our current knowledge about cervical mucus from both a clinical and basic research perspective.

View Article and Find Full Text PDF

short interval repeat pregnancy increases maternal and neonatal morbidity, and provision of postpartum contraception provides primary protection against these adverse outcomes. Confusion regarding effects on breast feeding and thrombosis risk delaying initiation of contraception in the immediate post-partum interval. Delaying contraception provision until the 6-week postpartum visit misses many women who either do not attend or have resumed ovulation and/or intercourse prior to this visit.

View Article and Find Full Text PDF

Aims: Type 3 long QT syndrome (LQT3) is caused by gain-of-function mutations in the cardiac sodium channel gene (SCN5A). Previous reports on the long-term use of sodium channel blockers in LQT3 are sparse. The objective of the current study was to evaluate the long-term safety and efficacy of flecainide therapy in patients with LQT3 who carry the D1790G SCN5A mutation.

View Article and Find Full Text PDF

Psychological effects related to systemic lupus erythematosus (SLE) are tremendous. While a variety of psychological treatments have been applied to assist SLE patients, the effects of mindfulness practice were never documented in SLE. Mindfulness-based psychotherapy includes several techniques, including body-scan, breathing exercises, and full awareness during daily activities.

View Article and Find Full Text PDF